ClinConnect ClinConnect Logo
Search / Trial NCT05335070

Reducing Pain From Wisdom Molar Extractions

Launched by RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY · Apr 13, 2022

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Temporo Masseteric Nerve Block Twin Block Prescription Opioids Acute Post Extraction Pain

ClinConnect Summary

This clinical trial is focused on finding a better way to manage pain for people having their lower wisdom teeth removed. Researchers are testing a new local anesthetic injection called the Temporo-masseteric Nerve Block, which may help reduce the pain experienced during and after the dental procedure. Participants in the study will receive the injection before their surgery, and then they will be asked about their pain levels and any pain medications they took during the first week after the extraction. They will also attend a follow-up visit eight days later to share their experiences.

To be eligible for this study, participants need to be at least 18 years old and up to 64 years old, in good overall health, and able to understand and agree to the study. They should not be pregnant and must have access to a smartphone and the internet to participate. If you join this trial, you can expect to receive care from dental professionals and contribute to research that could improve pain management for future patients.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age 18 years of age or older (up to 64 years)
  • Any demographic
  • ASA 1 and 2 (mild or absent systemic illnesses, deemed fit for undergoing dental extractions under intravenous sedation)
  • Not pregnant (as will not qualify to undergo procedure under intravenous sedation as part of routine standard-of-care)
  • Adequate mental ability to understand and provide informed consent
  • Has smart phone and internet connection
  • Exclusion Criteria:
  • Age older than 64 years (because they are poor candidates for undergoing procedures under intravenous sedation)
  • Pregnant
  • Incapable of providing informed consent
  • Any systemic condition that renders the patient at higher risk for complications under intravenous sedation
  • Documented allergy to the dental local anesthetic
  • Inability to tolerate any of the commonly used pain medications such as combination opioids, acetaminophen (Tylenol®) or ibuprofen (Motrin® or Advil®)
  • Limitation in adequate mouth opening in presence/absence of pain

About Rutgers, The State University Of New Jersey

Rutgers, The State University of New Jersey, is a prestigious public research university renowned for its commitment to advancing medical science and public health. As a leading clinical trial sponsor, Rutgers leverages its extensive academic resources, cutting-edge facilities, and a diverse team of experts to conduct innovative research that addresses critical health challenges. The university fosters collaboration across disciplines, engaging in partnerships with healthcare institutions and industry leaders to enhance the development of novel therapies and improve patient outcomes. With a strong emphasis on ethical standards and regulatory compliance, Rutgers is dedicated to advancing clinical knowledge while prioritizing participant safety and well-being in all of its research endeavors.

Locations

Newark, New Jersey, United States

Patients applied

0 patients applied

Trial Officials

Gayathri D Subramanian, PhD, DMD

Principal Investigator

Rutgers School of Dental Medicine

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials